ABSTRACT
Rash (sic) (<1%) Sensitivity (sic) [1] Stevens-Johnson syndrome [2] Toxic epidermal necrolysis [5] Urticaria [10] Vasculitis [2]
Hair Hair – alopecia [1]
Nails Nails – changes (sic) [1]
Hematopoietic Hemophilia [1]
Cardiovascular Flushing [1]
Other Anaphylactoid reactions [13] Death [2] Dysgeusia [1] Headache Hypersensitivity (<1%) [5] Rhabdomyolysis [3]
Trade name: Diamox (Wyeth) Other common trade names: Acetazolam; Ak-Zol; Dazamide; Defiltran; Diuramid; NovoZolamide Indications: Epilepsy, glaucoma Category: Anticonvulsant; Carbonic anhydrase inhibitor; Sulfonamide diuretic Half-life: 2-6 hours Clinically important, potentially hazardous interactions with: ephedra, lithium
Reactions
Skin Acute generalized exanthematous pustulosis (AGEP) [2]
Bullous eruption (<1%) [1] Erythema multiforme [2] Exanthems [2] Frostbite [1] Lupus erythematosus [1] Photosensitivity Pruritus Purpura [1] Pustular psoriasis [1] Pustules [1] Rash (sic) (<1%) Rosacea [1] Stevens-Johnson syndrome Toxic epidermal necrolysis (<1%) [1]
Urticaria
Hair Hair – hirsutism [1]
Hematopoietic Thrombocytopenia [1]
Other Ageusia Anaphylactoid reactions [3] Anosmia Dysgeusia (>10%) (metallic taste) [3] Extravasation [1] Headache Myalgia [1] Paresthesias (<1%) [1] Tinnitus Xerostomia (<1%)
*Note: Acetazolamide is a sulfonamide and can be absorbed systemically. Sulfonamides can produce severe, possibly fatal, reactions such as toxic epidermal necrolysis and Stevens-Johnson syndrome
Synonym: D2E7 Trade name: Humira (Abbott) Indications: Rheumatoid arthritis Category: Anti-TNF-alpha monoclonal antibody Half-life: 10-20 days
Reactions
Skin Allergic reactions (sic) (1%)
Carcinoma Cellulitis
Erysipelas Erythema multiforme [1] Flu-like syndrome (7%) Fungal dermatitis Herpes zoster Infections (5%) Lupus erythematosus (<0.1%) Lymphoma [1] Melanoma Peripheral edema Rash (sic) (12%) Upper respiratory infection (17%)
Other Back pain (6%) [1] Death Headache Injection-site edema (15.2%) Injection-site erythema (15.2%) Injection-site pain (12%) Myasthenia Paresthesias Tendinitis Tremor Tuberculosis [1]
Note: TNF blocking agents may lead to serious infections, lymphoma, or fatalities, particularly in patients receiving concomitant immunosuppressive therapy. Patients should be evaluated for latent tuberculosis prior to treatment with adalimumab.
